Interferon alfa-n3

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Interferon Sciences, Purdue Frederick

Conditions

HIV Infections

Phase 1

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

CompletedNCT00002078

Purdue FrederickHIV Infections

Updated: 2005-06-24

Unknown Phase

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

CompletedNCT00000844

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2002-06-30Target: 560Updated: 2021-11-03

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

CompletedNCT00002012

Interferon SciencesHIV Infections

Target: 45Updated: 2005-06-24

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

CompletedNCT00002018

Interferon SciencesHIV Infections

Target: 60Updated: 2005-06-24